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Abstract. To investigate the systemic signs of immune-inflammatory responses in Alzheimer’s disease (AD), in the present study
we have analyzed blood lymphocyte subsets and the expression of activation markers on peripheral blood mononuclear cells
(PBMCs) from AD patients and age-matched healthy controls (HC) activated in vitro by recombinant amyloid-β peptide (rAβ42).
Our study of AD lymphocyte subpopulations confirms the already described decrease of the absolute number and percentage of
B cells when compared to HC lymphocytes, whereas the other subsets are not significantly different in patients and controls.
We report the increased expression of the activation marker CD69 and of the chemokine receptors CCR2 and CCR5 on T cells
but no changes of CD25 after activation. B cells are also activated by rAβ42 as demonstrated by the enhanced expression of
CCR5. Moreover, rAβ42 induces an increased expression of the scavenger receptor CD36 on monocytes. Some activation
markers and chemokine receptors are overexpressed in unstimulated AD cells when compared to controls. This is evidence of
the pro-inflammatory status of AD. Stimulation by rAβ42 also induces the production of the pro-inflammatory cytokines IL-1β,
IL-6, IFN-γ, and TNF-α, and of the anti-inflammatory cytokines IL-10 and IL-1Ra. The chemokines RANTES, MIP-1β, and
eotaxin as well as some growth factors (GM-CSF, G-CSF) are also overproduced by AD-derived PBMC activated by rAβ42.
These results support the involvement of systemic immunity in AD patients. However, our study is an observational one so we
cannot draw a conclusion about its contribution to the pathophysiology of the disease.
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INTRODUCTION
Alzheimer’s disease (AD) is a heterogeneous and
progressive neurodegenerative disease that in Western
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societies accounts for the majority of clinical senile de-
mentia. Since no early peripheral and reasonable signs
of the disease have been identified so far, diagnosis
can be made with firmness only upon brain autopsy.
Moreover, no treatment is yet available to end or turn
round the disease; existing drugs are only able to relieve
symptoms for some time [1,2].
Pathological changes in the AD brain include neu-
ronal loss, senile plaques, and neurofibrillary tangles.
Together with the presence of intraneural tangles, con-
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sisting of phosphorylated tau-proteins, senile plaques
are the hallmark of the pathological diagnosis of AD.
However, the increased production of amyloid-β (Aβ)
from the amyloid-β protein precursor and its brain ac-
cumulation and deposit in the senile plaques lead to
inflammation and neuronal damage [3]. Depending on
whether the 40th or the 42nd amino acid in C-terminus
is the last of the Aβ protein, it consists of two ma-
jor forms, Aβ40 and Aβ42. The latter tends to cluster
into oligomers, forming Aβ fibrils that deposit as mi-
crostructures, amyloid plaques, and it is the predomi-
nant form that accumulates in the brain parenchyma of
AD patients. Senile plaques result from the accumula-
tion of several other proteins and an inflammatory reac-
tion around deposits of amyloid. In addition, plaques
contain dystrophic neurites, activated microglia, and
reactive astrocytes. Aggregated amyloid fibrils and in-
flammatory mediators secreted by microglial and as-
trocytic cells contribute to neuronal dystrophy [3,4].
Inflammation clearly occurs in pathologically vul-
nerable regions of the AD brain, and it does so with
the full complexity of local peripheral inflammatory
responses [5]. The microglia activation can be due to
local or systemic inflammation. In fact, a strong local
inflammatory stimulus such as a previous head trauma
is a risk factor for AD and several epidemiological stud-
ies clearly show that blood elevations of acute phase
proteins, markers of systemic inflammatory stimuli,
may be risk factors for cognitive decline and dementia.
Furthermore, in experimental animals chronic systemic
inflammatory response induced by lipopolysaccharide
administration also induces glial activation. After ac-
tivation, the microglia cells modify their morphology
and become tissue macrophages producing inflamma-
tory mediators [3,6]. Accordingly, case-control studies
clearly demonstrate the role of inflammatory genes in
AD [3,7,8]. In particular, two recent meta-analyses by
our group have underscored the role of cytokine poly-
morphisms in AD susceptibility, hence indicating the
role of immune-inflammatory responses in AD [9,10].
Aβ induces a local immune response involving glial
cells and astrocytes. The innate immunity tries to clear
Aβ and induces the production of inflammatory pro-
teins such as complement factors, acute-phase proteins,
pro-inflammatory cytokines, and chemokines that will
be chronically produced and can induce neurotoxici-
ty [5,11].
Although much evidence suggests the involvement
of a systemic immune response in AD, it is poorly char-
acterized [12]. Indeed, blood derived cells seem to
accumulate in the AD brain [13], while other studies
have shown changes in the distribution and reactivity
of immune cells in the blood [12,14–16]. As reviewed
by Britschgi and Wyss-Coray [12], many studies have
shown that there is communication between central and
systemic immune responses. In particular neuroinflam-
mation induces the efflux of central nervous system
(CNS) proteins, such as Aβ, or inflammatory mediators
across the blood-brain-barrier (BBB); this may cause
systemic immune reaction and recruitment of myeloid
or lymphocytic cells into the CNS [12]. Thus, commu-
nication between the CNS and immune system in AD
could influence both the lymphocyte distribution in the
blood and the production of immune mediators [12].
Indeed peripheral blood mononuclear cells (PBMCs)
from AD patients produce higher levels of some cy-
tokines, such as interleukin (IL)-1β and IL-6 compared
to PBMC from control subjects [17]. Other studies have
shown that Aβ stimulates macrophage inflammatory
protein (MIP)-1α overexpression on peripheral T cells
and its receptor CCR5 expression on brain endothelial
cells for T cells crossing BBB [18].
In addition, the production of Regulated on Acti-
vation, Normal T Expressed and Secreted (RANTES)
by AD PBMCs seems to increase after stimulation by
Aβ [19]. Moreover, an immune disregulation was re-
cently documented as dramatic alterations on CD4+
subsets in patients with mild AD have been report-
ed. In particular, decreased percentages of na ı¨ve cells
and an increase of memory cells, an increased num-
ber of CD4+ lymphocytes that lack the co-stimulatory
molecule CD28, and a reduction of CD4+CD25high T
regulatory cells (Treg) have been observed [20].
These data suggest a significant involvement of both
the innate and acquired immunity in AD patients, al-
though there are not enough data to determine if these
are the causes or the consequences of the disease. To
gain insight into this topic, we have investigated some
basic immune parameters in patients with AD, and we
have performed in vitro activation studies of AD PBM-
Cs with recombinant Aβ (rAβ42) to evaluate cellular re-
activity to the peptide and the cytokine and chemokine
production.
MATERIALS AND METHODS
Subjects
Diagnosis of probable AD was according to standard
clinical procedures and followed the NINCDS/ADRDA
and DSM-III-R criteria [21,22]. Cognitive perfor-
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mance and alterations were measured according to the
Mini Mental State Examination (MMSE) and the Glob-
al Deterioration Scale. All AD cases were defined as
sporadic because their family history did not mention
any first-degree relative with dementia. The population
of AD consisted of 40 patients from Sicily (27 wom-
en and 13 men; age range: 64–86 years; mean age:
78.4± 7.6). AD patients included in the study did not
present major co-morbidity such as cancer, symptomat-
ic (present or previous) cardiovascular diseases, and
major inflammatory diseases such as autoimmunity and
infections. Eighteen of them were under treatment for
hypertension and/or diabetes with drugs not known to
affect the immune system. According to MMSE, 16 pa-
tients were affected by severe dementia (< 17), where-
as the remaining 24 were affected by moderate grade of
dementia (> 17< 24). Patients with vascular dementia
were not included in the study. Since treatment with
acetyl-cholinesterase inhibitors may modulate cytokine
expression [23], patients were included before starting
that therapy. Healthy controls (HC) were 25 unrelated
individuals (15 women and 10 men; age range: 63–85;
mean age 77.5± 7.2) randomly selected from a retire-
ment home. These subjects had complete neurologi-
cal examinations and were judged to be in good health
based on their clinical history and blood tests (complete
blood cell count, erythrocyte sedimentation rate, glu-
cose, urea nitrogen, creatinine, electrolytes, C reactive
protein, liver function tests, iron, proteins, cholesterol,
triglycerides). The controls were collected from the
same population as the patient cohort. The Universi-
ty Hospital Ethics Committee approved the study, and
informed consent was obtained from all guardians of
patients and controls according to Italian law.
Whole blood was collected by venopuncture in va-
cutainer tubes containing ethylenediamine tetraacetic
acid. The samples were kept at room temperature and
used within 2 h for the various experiments. Lympho-
cyte subsets were analyzed in 40 AD and 25 HC. Cell
cultures for activation and cytokine production were
performed on PBMCs from 18 AD and 15 HC random-
ly selected, taking into account gender, age range, and
the ratio between severe and moderate AD. In fact, we
studied 11 patients affected by moderate AD (4 men
and 7 women, mean age 79.6± 1.3), 7 patients affected
by severe AD (2 men and 5 women, mean age 81.0 ±
1.5), and 15 HC (6 men and 9 women, mean age 78.5±
1.2).
Preparation and characterization of rAβ42
Isolation and purification of rAβ42 were performed
as described by Carrotta et al. [24]. To obtain small
oligomers, rAβ42 was dissolved in double-distilled
H2O (ddH2O) to a final concentration of 1.4 mM and
incubated at 37◦C for 96 h. Immediately after dis-
solution (time 0), and after incubation, aliquots were
taken and stained adding thioflavin-T (ThT) at a fi-
nal concentration of 70 µM and applied to microscope
slides [25]. The presence of aggregates with dimen-
sions in the range of micrometers was visualized with
the fluorescence optics of an Axioscop 2 microscope
(Zeiss, USA). The images were captured using an Axio-
cam digital camera interfaced with a computer. More-
over, rAβ42 at time 0, and after incubation at 37◦C for
96 h, was analyzed by Western blot. Analysis of the
samples was carried out using SDS-PAGE, and after
running, the gel was transferred to nitrocellulose and
the filter was incubated with anti-Histidine (anti-His)
1:5000 (Pierce, Rockford, IL, USA) [24].
Cell cultures
PBMCs were separated by centrifugation with
Ficoll-Lympholyte (Cedarlane Laboratories Limited,
Ontario, Canada) and washed twice in PBS. Viability
was assessed by trypan blue dye exclusion. The viable
cells (95–98% of the preparation) were re-suspended at
the concentration of 1 × 10 6/µl in complete medium
composed of RPMI 1640 (Euroclone, Devon, UK) sup-
plemented with 10% heat-inactivated fetal calf serum
(Euroclone), 1% penicillin/streptomycin, 10 mM HEP-
ES, and 1 mM L-glutamine.
Cells were cultured in 24-well flat-bottom plates at
1.5× 106 cells per well in RPMI medium. The PBMCs
were either unstimulated or stimulated by oligomeric
rAβ42 (10 µg/ml) obtained as described above. For the
chemokine receptor expression study, the PBMCs were
either unstimulated or stimulated by phytohaemagglu-
tinin (PHA) (3 µg/ml), anti-CD3 (α-CD3) (1 µg/ml),
rAβ42 (10 µg/ml), for 48 h at 37◦C in a humidified 5%
CO2 atmosphere. The cells were then collected and
used for flow cytometry.
Flow cytometry
In order to evaluate the T lymphocyte subsets in both
AD patients and HC, fresh samples were stained using
the following monoclonal antibodies: anti-CD3, anti-
CD4, anti-CD8, anti-CD16, anti-CD19, anti-TCR γδ.
In order to evaluate the activation of PBMC obtai-
ned from AD patients and HC, the in vitro cultured cells
were stained as follows: anti-CD25FITC/anti-CD3PE
/anti-CD19PECy5, anti-CD69FITC/anti-CD3PE/anti-
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Fig. 1. Characterization of rAβ42. A) Western blot of rAβ42 incubated with anti-His, immediately after dissolution in ddH2O (time 0) and after
incubation for 96 h at 37◦C. On the right, molecular weight standards are indicated. B) Staining with ThT. Fluorescence images of representative
areas of the observation field at time 0 and at 96 h.
CD19PECy5, anti-HLADRFITC /anti-CD19PE/anti-
CD80PE−Cy5 and anti-CD36FITC/anti-CD14+PE/
CD80PE−Cy5. The activation-induced expression
of chemokine receptors was evaluated by staining
cultured cells with the following monoclonal an-
tibodies: anti-CD192 (CCR2)
AlexaFluor 647
, anti-
CD193 (CCR3)PE and anti-CD195 (CCR5)PE−Cy5
on B (CD19+) and T (CD3+) cells. All monoclon-
al antibodies were directly coupled either to fluores-
cein isothiocyanate (FITC), R-phycoerythrin (R-PE),
phycoerytrin-Cyanine 5 (PE-Cy5), or Alexa Fluor
647 (Pharmingen,BD Bioscience, Mountain View, CA,
USA).
All the measurements were made with a FACSCal-
ibur flow cytometer (Becton Dickinson, San Jose, CA,
USA) with the same instrument setting. At least 104
cells were analyzed using CellQuestPro (Becton Dick-
inson, San Jose, CA, USA) software.
Cytokine production assay
The supernatants of the cultured PBMCs were col-
lected and the following cytokines and chemokines
were evaluated using a Bio-Plex kit (BioRad, Munich,
Germany): IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-
7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, ba-
sic fibroblast growth factor (BFGF), eotaxin, granulo-
cyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), int-
erferon(IFN)-γ, IFN-γ-inducible protein (IP)-10, mon-
ocyte chemoattractant protein (MCP)-1, MIP-1α, MIP-
1β, platelet-derived growth factor-bb (PDGF-bb),
RANTES, tumor necrosis factor (TNF-α), and vascu-
lar endothelial growth factor (VEGF). 50 µl per sample
were analyzed on the Luminex 100 (BioRad) according
to manufacturer’s instructions.
Statistical analysis
Values (percentage or MFI), given as the mean ±
SEM, were compared using one-way analysis of vari-
ance (ANOVA). Differences were considered signifi-
cant when a p value< 0.05 was obtained by comparison
of the two different groups.
RESULTS
Characterization of rAβ42
To confirm that rAβ42, prepared as previously de-
scribed, forms oligomers in vitro, an aliquot of the
samples at time 0 and at 96 h obtained as described
in the previous section was incubated with anti-His.
As shown in Fig. 1A, on the basis of the molecular
weight of the detected bands, we established that only
monomers were present in the sample at time 0, and
different small oligomers (ranging from 12 to 24 kDa)
in the sample at 96 h. Furthermore, after staining with
ThT no visible structures in the sample at time 0 were
detectable, whereas, small structures of dimensions up
to 2 µm in the 96 h sample were present (Fig. 1B).
Therefore, the preparations used in our experiments
were made up of oligomers.
Lymphocyte subsets
Table 1 shows the percentage and the absolute num-
ber of the main lymphocyte subpopulations evaluated
in 25 HC and 40 AD patients. As shown, and as pre-
viously reported by others [26–28], we report a signif-
icant decrease in the percentage and absolute number
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Table 1
Lymphocyte subpopulations in 40 AD subjects and 25 HC. Data are expressed as Mean ± SD of the percentage and as absolute
number
Subpopulations HC % (Mean ± SD) HC (Absolute number/µL) AD % (Mean ± SD) AD (Absolute number/µL)
CD3+ 67.3 ± 11.8 1196 ± 444 68.4 ± 9.2 1260 ± 420
CD4+ 44.3 ± 9.6 801 ± 310 45.7 ± 8.9 845.6 ± 340
CD8+ 20.0 ± 10.5 373 ± 214 21.0 ± 8.9 361 ± 160
CD19+ 9.8 ± 5.3 184 ± 128 7.0 ± 3.7∗ 110 ± 54∗
CD3−CD16+ 17.2 ± 9 350 ± 195 15.7 ± 6.7 319 ± 165
γδ+ 3.0 ± 3.3 45 ± 55 2.5 ± 1.8 54 ± 39
Significance has been evaluated by ANOVA test. AD vs. HC∗p = 0.01.
Fig. 2. Percentage (Mean ± SEM) of expression of early activation markers CD25 and CD69 on T (CD3+) (panel A) and B (CD19+) (panel B)
cells of HC (n = 15) and AD subjects (n = 18) cultured in medium (white) or with rAβ42 (black). Panel C shows the MFI (Mean ± SEM)
of expression of CD80 and HLA-DR on B cells of HC (n = 15) and AD subjects (n = 18) cultured in medium (white) or with rAβ42 (black).
Statistical analysis was performed by ANOVA test. Significant values are indicated, p1 = CD25 expression on unstimulated (medium) AD cells
vs. unstimulated HC cells; p2 = CD69 expression on rAβ42-stimulated cells from AD vs. rAβ42-stimulated cells from HC. Concerning B
cells, no significant differences were observed for CD25 expression on rAβ42-stimulated cells from AD vs. rAβ42-stimulated cells from HC, for
CD69 expression on unstimulated cells (medium) AD vs. unstimulated HC cells, nor for both CD80 and HLA-DR between the groups studied.
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Fig. 3. MFI (Mean ± SEM) of expression of CD36 (panel A) and CD80 and HLA-DR (panel B) on monocytes (CD14+) of HC (n = 15) and
AD (n = 18) subjects cultured in medium (white) or with rAβ42 (black). Statistical analysis was performed by ANOVA test. Significant values
are indicated, p1 = unstimulated (medium) AD cells vs. unstimulated HC cells, p2 = rAβ 42-stimulated cells from AD vs. rAβ42-stimulated
cells from HC. No significant differences were observed for CD36 expression on unstimulated cells (medium) HC vs. stimulated HC cells, and
on unstimulated (medium) AD cells vs. stimulated AD cells nor for the expression of CD80 and HLA-DR in the groups studied.
of circulating B lymphocytes of AD patients compared
to HC. No significant differences have been instead ob-
served between the two groups concerning the other
lymphocyte subsets.
PBMC activation
To study the response to Aβ, we stimulated PBMCs
from 18 AD and 15 HC (see Materials and Methods)
with the oligomeric form of rAβ42 and analyzed the
expression of the activation markers CD25 and CD69
on T and B lymphocytes, and of CD80 and HLA-DR
on B lymphocytes.
We report (Fig. 2a) a significantly higher expression
of CD25 on unstimulated T cells from AD patients
compared to unstimulated T cells from HC, whereas
the stimulation by rAβ42 does not induce significant
differences between the two groups. On the contrary,
CD69 is not significantly higher in unstimulated T cells
from AD patients and is significantly overexpressed af-
ter stimulation by rAβ42. The expression of CD25,
CD69, HLA-DR, and CD80 on B cells showed no sig-
nificant differences, after stimulation, between the two
groups studied. We again observed that lymphocytes
of AD patients showed a basically higher, but not sig-
nificant, expression of some of these activation markers
(Fig. 2b, c).
We have also evaluated the activation of monocytes
after stimulation by rAβ42. We have observed a higher
basal expression of CD36, a class B scavenger receptor
that interacts with fibrillar Aβ [25,29], and a signifi-
cant different expression of this receptor after stimula-
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Fig. 4. MFI (Mean ± SEM) expression of CCR2 and CCR5 on CD3+ T cells (panels a, b) and CD19 B (panels c, d) peripheral lymphocytes
obtained from 15 HC subjects and 18 AD patients and cultured for 48 h in presence (black) or absence (white) of rAβ42. Statistical analysis was
performed by ANOVA test. P values are calculated comparing the MFI± SEM of positive cells obtained from unstimulated and rAβ42-stimulated
cells. Comparing unstimulated vs. stimulated cells we obtain significant values in: a) CCR2 expression on T cells from AD patients, (unstimulated
vs. stimulated p = 0.01); b) CCR5 expression on T cells from AD patients, (unstimulated vs. stimulated p = 0.05); c) CCR2 expression on
B cells from AD patients, (unstimulated vs. stimulated not significant); d) CCR5 expression on B cells from AD patients, (unstimulated vs.
stimulated p = 0.03). Concerning the unstimulated PBMCs significant difference are observed comparing CCR5 expression on T cells from HC
and AD. Indeed there is a higher basal expression of CCR5 on AD patients (HC vs. AD p = 0.05).
tion by rAβ42 between patients and controls (Fig. 3a).
In contrast, analyzing the expression of CD80 and of
HLA-DR on monocytes, we have not seen any variation
between the groups studied (Fig. 3b).
In a further set of experiments, we have evaluat-
ed the expression of CCR2 (MCP-1 receptor), CCR3
(RANTES and eotaxin receptor) and of CCR5 (MIP-
1α, MIP-1β, and RANTES receptor) on T (CD3+) and
B (CD19+) lymphocytes.
As shown (Fig. 4a-d), CCR2 (Fig. 4a) and CCR5
(Fig. 4b) are overexpressed on T cells stimulated by
rAβ42, in both groups, although the significance was
attained only in AD patients. In addition, the basal
expression of CCR5 on the CD3+ cells is significant-
ly higher in AD patients. The evaluation of the same
receptors on B cells, after activation by rAβ42, shows
a significantly greater expression of CCR5 in AD pa-
tients, and not in controls. No differences were ob-
served for CCR2 expression on CD19+ cells (Fig. 4c,
d) as well as for CCR3 expression on T and B cells
(data not shown).
The stimulation of cells from HC and AD by PHA
or α-CD3, used as further control, does not induce
the expression of these chemokine receptors either in
HC or AD patients. Figure 5 shows a typical experi-
ment that compares the response of cells from AD pa-
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Fig. 5. Representative expression of CCR2 and CCR5 on CD3+ T cells (panels a, b) and CD19 B cells (panels c, d) obtained from one AD
patient, and cultured for 48 h in presence of PHA (. . . . . . ), α-CD3 (. . . . . . ), rAβ42 (—), or none (RPMI) (—).
tients to the different stimuli used (PHA, α-CD3, and
rAβ42). As shown (Fig. 5a, b), CD3 cells overexpress
CCR2 (panel A) and CCR5 (panel B) when stimulated
by rAβ42, whereas the stimulation by either PHA or
α-CD3 gives a fluorescence intensity like that of un-
stimulated T cells. Panel C and panel D depict the re-
sults obtained stimulating CD19 B cells. As shown, no
changes are observed in the expression of CCR2, using
rAβ42, PHA or α-CD3. Activation by rAβ42 causes
an increased of expression of CCR5 on B cells, where-
as the stimulation by either PHA or α-CD3 gives a
fluorescence intensity like that of unstimulated B cells.
AD patients (N = 18) of this subgroup showed the
same changes in lymphocyte populations (i.e., B lym-
phocyte decrease) as well as in the initial group (7.0±
2.2 versus 7.0 ± 3.7). None of these results were af-
fected by the gender and the MMSE of AD patients;
in particular no differences have been observed com-
paring data obtained from subjects with severe (< 17)
versus moderate AD.
Cytokine production
We have analyzed the production of cytokines,
growth factors, and chemokines in supernatants ob-
tained from AD- and HC-PBMC cultured for 48 h in the
presence/absence of the oligomeric form of rAβ42. As
shown in Table 2, after stimulation by rAβ42, PBMC
obtained from AD patients significantly increased the
production of both pro-inflammatory cytokines (IL-1β,
IL-6, IFN-γ, TNF-α) and anti-inflammatory cytokines
(IL-10, IL-1ra) as well as some growth factors (GM-
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Table 2
Percent of increase of cytokines, growth factors, and chemokines secretion by PBMCs of 15 HC and 18 AD patients in pres-
ence/absence of rAβ42. The percentage was calculated using the following formula: stimulated-unstimulated/unstimulated
x 100. In bracket % of increase of p25–p75 values. Significance has been evaluated by ANOVA test. n.s. = not significant
Cytokines rAβ42 HC vs. medium HC Increase (%) rAβ42 AD vs. medium AD Increase (%) p1 p2
(median and p-25–p75 values) (median and p-25–p75 values)
IL-1β 4 (0–22) 211 (133–285) n.s. 0.01
IL-1ra 66 (0–258) 202 (152–288) n.s. 0.006
IL-6 0 (0–151) 410 (280–532) n.s. 0.01
IFN-γ 0 (0–52) 106 (84–134) n.s. 0.002
TNF-α 0 (0–168) 63 (35–104) n.s. 0.02
IL-10 0 (0–0) 236 (100–542) n.s. 0.03
Growth Factors
GM-CSF 0 (0–90) 77 (62–100) n.s. 0.003
VEGF 0 (0–322) 32 (10–82) n.s. n.s.
PDGF bb 57 (0–283) 14 (0–26) n.s. n.s.
G-CSF (0–280) 547 (367–1367) n.s. 0.01
Chemokines
Eotaxin 0 (0–128) 114 (98–141) n.s. 0.003
MIP-1α 188 (0–577) 1710 (163–5032) n.s. n.s.
MIP-1β 74 (0–377) 465 (152–639) n.s. 0.02
RANTES 275 (0–955) 123 (57–206) n.s. 0.05
MCP-1(MCAF) 0 (0–0) 0 (0–0) n.s. n.s.
p1 = Significance of differences between Medium and rAβ42 of HC; p2 = Significance of differences between Medium
and rAβ42 of AD.
CSF, G-CSF) and some chemokines (eotaxin, MIP-
1β, RANTES) when compared to the cells cultured in
medium. On the contrary, cells obtained from HC do
not show any significant increase in the production of
these cytokines.
By analyzing data according both to gender and to
AD severity, no differences were observed. As pre-
viously stated, AD patients of this subgroup showed
the same changes in lymphocyte populations (i.e., B
lymphocyte decrease) as well as in the initial group.
DISCUSSION
Many studies have reported alterations of the im-
mune system in AD and the involvement of both the
innate and acquired branches of the immune system [3,
12]. In this paper, we report data obtained studying
cells and factors involved in immune response in AD
patients.
The “peripheral lymphocytes” topic has been exam-
ined by different groups with conflicting results [12,
20,26–28], and currently there is no general consen-
sus on the modifications of lymphocyte subsets in AD
patients [12]. Our study of AD lymphocyte subpopu-
lations confirms the already described decrease of the
absolute number and percentage of B cells when com-
pared to HC lymphocytes [26–28], whereas the other
subsets are not significantly different in patients and
controls. This decreased number of B cells is already
present in elderly when compared to young people [30].
Therefore, it suggests an exacerbation in AD of this
feature linked to a reduced output of B cells from bone
marrow [30]. This might be due to the well known
systemic pro-inflammatory status of AD patients [3,
6–10,31] and present results. On the T cell side, the
results reported in different studies are discordant with
each other. In fact, whereas our data are in agreement
with Speciale et al. [26], Xue et al. [28] show a signif-
icant reduction of CD3+, CD4+ and CD8+; Richartz-
Salzburger et al. [29] confirm the decrease of CD3+ T
cells and CD8+ T cells, but showed a slightly increase
of CD4+. On the other hand, as previously stated, dra-
matic alterations on CD4+ subsets in patients with mild
AD have been reported by Larbi et al. [20]. These dif-
ferences might be the result of methodological differ-
ences among the different studies, including inclusion
criteria of both AD patients and HC.
However, the finding that the B cell compartment
is modified in AD patients compared to HC, together
with the increased expression of the chemokine recep-
tor CCR5 on B cells, after stimulation by rAβ42, sug-
gests the involvement of B cells in the complex cellular
interactions active in AD patients. On the other hand,
rAβ42 stimulation does not change the expression of the
activation markers CD25 and CD69 on B cells: it is an
unexpected result since B cells can produce antibodies
against Aβ [32].
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On the other hand, we report a good response of
T cells to Aβ; in fact the CD69 activation marker
is overexpressed in rAβ42-stimulated AD cells when
compared to HC stimulated cells. Furthermore, the
chemokine receptors CCR2 and CCR5 are overex-
pressed in AD cells after in vitro stimulation by rAβ42.
This is an interesting result since the reactivity and abil-
ity of T cells to respond to the chemokines that can
be produced locally in the brain might explain the mi-
gration of T cells across the brain microvascular en-
dothelial cells occurring in AD [12]. It is notewor-
thy that some activation markers and chemokine recep-
tors are overexpressed in unstimulated AD cells when
compared to controls. This is evidence of the pro-
inflammatory status of AD [3,6–10,31]. The increase
of CD25+ T lymphocytes in cells from AD patients cul-
tured in medium only might suggest an increase of Treg
(CD4+CD25high). However, using as marker of Treg
FOXP3, Rosenkranz and colleagues [33] did not report
their increase in PBMC just collected from AD patients
when compared to elderly donors. On the contrary,
Larbi and coworkers [20] show that CD4+CD25high
are reduced in PBMC just collected from AD when
compared with both young and old donors. Our ex-
perimental conditions are different as we observe an
increase of basal expression of CD25 on total CD3 cul-
tured for 48 h with medium only. So, in our opinion,
the increase of CD3+CD25+ cells in AD patients might
be the consequence of the basal inflammatory milieu of
AD patients [3,6–10,31].
The increased expression of the scavenger receptor
CD36 on monocytes from AD subjects in unstimulat-
ed and stimulated cultures is also an intriguing result
as circulating monocytes might efficiently bind plas-
matic Aβ. That causes the production of cytokines,
chemokines, and reactive oxygen species, hence acti-
vating the signaling cascade useful for cellular migra-
tion, adhesion, and phagocytosis. In addition, the en-
gagement of monocytes might render these cells more
efficient in T cell activation [34].
Our data show that, in addition to expressing
chemokine receptors, PBMC in vitro stimulated by
rAβ42 are able to produce different chemokines and
cytokines, rendering these cells active players in the
inflammatory response in AD patients. The study of
in vitro production of cytokines shows a significant-
ly higher production of inflammatory cytokines IL-1β,
IL-6, and TNF-α and of IFN-γ by AD in vitro stimulat-
ed PBMC. This is not a surprising result as inflamma-
tion is a characteristic of AD [3] and a high responder
cytokine profile is associated with AD [9,10,32]. We
also report an increase of anti-inflammatory cytokines
IL-10 and IL-1ra, and we hypothesize that this increase
in vitro production should balance the higher in vit-
ro production of pro-inflammatory cytokines. Howev-
er, as previously stated, there is an efflux of amyloid
from CNS that can prime lymphocytes. Some authors
have demonstrated a reduction of both pro- and anti-
inflammatory cytokines, hence assuming a general im-
pairment of immune functions in AD patients, where-
as others have demonstrated a decrease of IL-10, an
increase of MIP1-α and an increase of IFN-γ, respec-
tively [12,18,19,26]. Methodological differences (mi-
togen or Aβ stimulation) among the different studies,
including inclusion criteria of both AD patients and
healthy controls, might explain the great variability of
data. Since monocytes are the main source of IL-6
and TNF-α and they possibly bind efficiently Aβ42 via
CD36, the pattern of cytokine production observed in
the present paper is that to be expected.
It has been demonstrated that peripheral T lympho-
cytes of AD patients produce higher MIP-1α levels than
age-matched controls [18]. This observation together
with the expression of the MIP-1α receptor CCR5 on
the human brain microvascular endothelial cells (HB-
MEC), might explain the migration of T cells across
the blood-brain barrier. Microglial cells also produce
MIP-1α. It has been demonstrated that MCP-1 via
CCR2 expressed on brain endothelial cells contribute
to increased brain endothelial permeability [12,18,35–
37]. Here we show a higher expression of CCR5 on T
and B lymphocytes, and of CCR2 on T cells stimulated
in vitro by rAβ42, participating in a vicious circle in the
brain.
In contrast to these data, in our system we do not
observe any significant overproduction of MIP-1α in
PBMC in vitro stimulated by rAβ42. This discrepan-
cy might be due to the different experimental system
since the production-binding of MIP-1α “in vivo” or
“in vitro” was assessed using HBMEC [18]. As previ-
ously described by others [38], our AD patients show
increased production of RANTES binding CCR5 al-
so, when compared to unstimulated cells of the same
donors. Finally, the results of MCP-1 production are
very unpredictable in the different individuals of the
two subject cohorts, so it is impossible to draw any
conclusion.
A higher level of chemokines after stimulation with
PHA has been demonstrated by other authors [38]. We
have not evaluated the production of cytokines and
chemokines from cells stimulated with αCD3 or PHA,
but in our system the stimulation with mitogens does
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not change the expression of CCR5 and CCR2 on T
and B cells.
Finally, cytokine, growth factor, and chemokine pro-
duction was obtained in a bulk culture preparation as
we are interested in an ex-vivo model of interaction
between different cells and factors. Furthermore, no
proliferation assay was performed, because in our sys-
tem no changes in IL-2 production were detectable af-
ter stimulation by rAβ42 in both AD and HC (data not
shown).
On the whole, our data demonstrate that immune-
inflammatory parameters are modified in PBMC ob-
tained from AD patients and stimulated in vitro by
rAβ42. Data on involvement of the immune system in
AD are controversial and difficult to fully understand.
The results obtained in our study can be the mirror of
T and microglial abilities in AD patients. Therefore,
these data on the activation of peripheral lymphocytes
by rAβ42 support the occurrence in AD of the systemic
activation of immune-inflammation [31,39,40], and, on
the other hand demonstrated by the high level of basal
activation. We know that the brain is not an immuno-
logically privileged site since peripheral immune cells
can influence local reactions and can be influenced by
local immune-inflammatory responses [12].
We contribute new information about soluble fac-
tors and cellular ligands that might be involved in the
pathogenesis or in the tissue damage observed in AD
patients. However, our study is an observational one;
hence we cannot draw a conclusion on its contribu-
tion to the pathophysiology of the disease. The knowl-
edge that senile plaques, a hallmark of AD (togeth-
er with neurofibrillary tangles) are formed by Aβ, has
suggested the design of immunotherapies with the aim
of removing or reducing the senile plaques from the
brain. Unfortunately clinical trials of Aβ vaccination
of AD patients show an unacceptable rate of menin-
goencephalitis [41]. On the other hand, intravenous
immunoglobulin (IVIg) has been proposed as a poten-
tial agent for AD immunotherapy because it contains
antibodies against Aβ. Accordingly, a retrospective
case-control analysis demonstrated that previous treat-
ment with IVIg is associated with a reduced risk of
developing AD [42]. Thus, this kind of study might be
useful to obtain biomarkers of AD for monitoring the
effectiveness of therapeutic interventions [43].
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